Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biktarvy
Pharma
In switching study, patients preferred J&J, ViiV drug over rival
A recent switch study found that a whopping 90% of HIV patients who responded to a ViiV questionnaire said they preferred Cabenuva over Biktarvy.
Fraiser Kansteiner
Jul 25, 2023 9:32am
ViiV, Gilead row escalates to feds after self-regulation fails
May 2, 2023 10:14am
Gilead handed its CEO Daniel O'Day a healthy pay bump in 2022
Mar 24, 2023 9:55am
European AIDS advocacy group keeps Gilead in the crosshairs
Mar 14, 2023 12:29pm
GSK's Cabenuva matches Gilead's Biktarvy in head-to-head study
Feb 22, 2023 11:00am
Gilead touts growth for HIV, cancer groups amid Veklury's fall
Feb 3, 2023 1:49pm